Tafasitamab-Parsaclisib Trial Termination Tempers Incyte Outlook

Incyte (INCY) announced an update on their ongoing clinical study.

Tafasitamab-Parsaclisib Basket Trial Halted

A Phase 1b/2a basket trial titled “A Phase 1b/2a Basket Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Combination Therapy With the Anti CD19 Monoclonal Antibody Tafasitamab and the PI3Kδ Inhibitor Parsaclisib in Adult Participants With Relapsed/Refractory Non Hodgkin Lymphoma or Chronic Lymphocytic Leukemia” was designed to test whether combining these agents could expand treatment choices for patients with relapsed blood cancers, an area where safety and durability remain critical.

The regimen pairs tafasitamab, an anti-CD19 antibody, with parsaclisib, a PI3Kδ inhibitor, aiming to boost immune targeting while curbing tumor growth across multiple lymphoma and leukemia cohorts.

The single-arm, open-label study allocated all participants to the combination therapy, lacked masking, and targeted treatment outcomes, focusing on safety, tolerability, and early response markers.

Key dates: study start in March 2021 signaled the launch of combination testing; primary completion in October 2025 marked data lock for main endpoints; estimated overall completion remains October 2025 given termination; the database was last updated February 2, 2026 to reflect the halted status and posted safety data.

For investors, the termination removes a potential growth lever for Incyte’s hematology pipeline and may dampen near-term sentiment, particularly as competing CD19 or PI3K programs from larger peers stay active; the setback underscores execution risk and keeps attention on Incyte’s other late-stage assets.

The study remains listed as terminated on ClinicalTrials.gov, where further details are available.

To learn more about INCY’s potential, visit the Incyte drug pipeline page.